Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
収録刊行物
-
- The Lancet Oncology
-
The Lancet Oncology 22 (7), 991-1001, 2021-07
Elsevier BV